Not Signed In -
Wilson's Disease |
Copper storage disease; Hepatolenticular Degeneration; Hepatolenticular degeneration syndrome; WD - Wilson's disease; Wilson disease; Wilson's disease; Wilson's disease |
Clinical Trial: A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
This study is currently recruiting patients.
|
Purpose
In this study, individuals complete and return a mail survey, specifically a 40 item scratch and sniff smell test.
| Condition |
|---|
| Parkinson Disease Parkinsonian Syndrome |
MedlinePlus related topics: Brain Diseases; Movement Disorders; Parkinson's Disease
Genetics Home Reference related topics: Parkinson disease
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Screening Evaluations for Neurologic Syndromes: Olfactory Testing in Relatives of Parkinson’s Disease Patients
Expected Total Enrollment: 600
Study start: October 2004; Expected completion: June 2008
Last follow-up: November 2007; Data entry closure: December 2007
This study would extend the findings of previous studies by characterizing the performance of the 40-item UPSIT in a cohort of first-degree relatives of Parkinson’s disease (PD) patients. The results would also validate the use of the University of Pennsylvania Smell Identification Test (UPSIT) as a mail-survey instrument. Once identified, these individuals could be followed as a potentially at-risk cohort to determine if the screening evaluation was predictive of later developing Parkinson’s disease. The results from this pilot study have the potential to guide the use of olfactory testing using the UPSIT as a screening tool, and to provide necessary preliminary data for planning clinical trials to prevent the occurrence of PD in at-risk individuals.
Eligibility
Ages Eligible for Study: 21 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Subject must be a first-degree relative of a PD patient with diagnosis confirmed by a movement disorders specialist at the Institute for Neurodegenerative Disorders
- Subject must not carry a diagnosis of PD or other neurodegenerative disorder
- Subject must be either at least 50 years old or within 10 years of the age of onset of their affected relative
- Subject must be a non-smoker
- Subject must have no other known reason for abnormal olfaction (e.g. nasal trauma)
Location and Contact Information
Christopher Meehan 203-401-4300 cmeehan@indd.org
Connecticut
Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States; Recruiting
Kenneth Marek, MD, Sub-Investigator
More Information
Publications
Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol. 2001 Jul;50(1):34-41.
DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003 Oct 31;302(5646):830-4. Review.
Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984 Mar;32(3):489-502.
Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration. 1995 Mar;4(1):93-7.
Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996 Jan;46(1):231-7.
Markopoulou K, Larsen KW, Wszolek EK, Denson MA, Lang AE, Pfeiffer RF, Wszolek ZK. Olfactory dysfunction in familial parkinsonism. Neurology. 1997 Nov;49(5):1262-7.
Montgomery EB Jr, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology. 1999 Mar 10;52(4):757-62.
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314-9.
Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology. 2002 Jan 22;58(2):179-85. Review.
Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1987 Jan;50(1):88-9.
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: November 16, 2004
ClinicalTrials.gov Identifier: NCT00096876
Health Authority: United States: Institutional Review Board (Awaiting confirmation)
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
